Abstract: A multi-layer laminated circuit board 10A of the present invention is formed by laminating together a multi-layer transformer 10, a multi-layer part sheet 30 formed with a multi-layer part, and a wiring sheet 50 formed with a circuit pattern. The multi-layer transformer 10 is incorporated into the multi-layer laminated circuit board 10A, and therefore a package for the multi-layer transformer 10 is omitted, and the wiring between the multi-layer transformer 10 and other components is reduced to a minimum.

Abstract: The multi-layer transformer 10 of the present invention comprises a composite sheet 14a comprising a center magnetic pattern 11a and peripheral magnetic pattern 12a that are formed at the center and periphery respectively, and a dielectric pattern 13a of a nonmagnetic body that is formed in a part except the center and periphery; a composite sheet 14b similarly comprising a center magnetic pattern 11b, peripheral magnetic pattern 12b and a dielectric pattern 13b; a primary winding 15a that is located on one face of the dielectric pattern 13a; a secondary winding 15b that is located on one face of the dielectric pattern 13b; and magnetic sheets 16a and 16b that hold the composite sheets 14a and 14b, primary winding 15a and secondary winding 15b from both sides and contact one another via the center magnetic patterns 11a and 11b and peripheral magnetic patterns 12a and 12b.

Abstract: The present invention is directed to a compound represented by formula (1): (wherein R1 represents an alkyl group which may have a substituent or an alkenyl group which may have a substituent; and each of R2 and R3 represents a hydrogen atom, an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group, or an alkynyl group, or R2 and R3 form, together with the nitrogen atom adjacent thereto, a nitrogen-containing saturated heterocyclic group which may have a substituent) and a drug composition containing the compound. The compound exhibits tumor necrosis factor (TNF-?) production inhibitory effect and improved absorption upon oral administration.

Abstract: The multi-layer transformer 10 of the present invention comprises a composite sheet 14a comprising a center magnetic pattern 11a and peripheral magnetic pattern 12a that are formed at the center and periphery respectively, and a dielectric pattern 13a of a nonmagnetic body that is formed in a part except the center and periphery; a composite sheet 14b similarly comprising a center magnetic pattern 11b, peripheral magnetic pattern 12b and a dielectric pattern 13b; a primary winding 15a that is located on one face of the dielectric pattern 13a; a secondary winding 15b that is located on one face of the dielectric pattern 13b; and magnetic sheets 16a and 16b that hold the composite sheets 14a and 14b, primary winding 15a and secondary winding 15b from both sides and contact one another via the center magnetic patterns 11a and 11b and peripheral magnetic patterns 12a and 12b.

Abstract: A multi-layer laminated circuit board 10A of the present invention is formed by laminating together a multi-layer transformer 10, a multi-layer part sheet 30 formed with a multi-layer part, and a wiring sheet 50 formed with a circuit pattern. The multi-layer transformer 10 is incorporated into the multi-layer laminated circuit board 10A, and therefore a package for the multi-layer transformer 10 is omitted, and the wiring between the multi-layer transformer 10 and other components is reduced to a minimum.

Abstract: The present invention is directed to a compound represented by formula (1): (wherein R1 represents an alkyl group which may have a substituent or an alkenyl group which may have a substituent; and each of R2 and R3 represents a hydrogen atom, an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group, or an alkynyl group, or R2 and R3 form, together with the nitrogen atom adjacent thereto, a nitrogen-containing saturated heterocyclic group which may have a substituent) and a drug composition containing the compound. The compound exhibits tumor necrosis factor (TNF-?) production inhibitory effect and improved absorption upon oral administration.

Abstract: A novel antibiotic designated as KA-6643 and having the formula, ##STR1## wherein R is hydrogen or --SO.sub.3 H.

Abstract: A-KA-6643-series antibiotic comprising at least one substance represented by any of the following formulae, or a salt or ester thereof: ##STR1## is effectively useful as an antibacterial and .beta.-lactamase inhibiting agent.

Abstract: An antibiotic KA-6643-A or a salt thereof having the formula: ##STR1## is produced by a process comprising the step of hydrolyzing an antibiotic KA-6643-B of the formula: ##STR2##

Abstract: Novel antibiotics of the following structure ##STR1## wherein R represents a moiety selected from the group consisting of hydrogen, --COCH.sub.2 NH.sub.2, --COCH.sub.2 NHCONH.sub.2 and --COCH.sub.2 NHCHO;process for preparation thereof; and biologically pure culture for use therein.

Abstract: An antibiotic substance KA-7038 selected from the group consisting of the compounds having formulae I to VII described in claim 1, mixtures thereof and acid addition salts thereof; an antibiotic composition composed of (i) antibiotically effective amount of aforesaid antibiotic substance KA-7038, and (ii) a pharmaceutically acceptable diluent or carrier. The antibiotic substance KA-7038 can be produced by cultivating an antibiotic substance KA-7038-producing strain belonging to genus Streptomyces, for example Streptomyces sp. KC-7038, and isolating the antibiotic substance KA-7038 from the culture broth.

Abstract: Novel antibiotics of the following structure ##STR1## wherein R represents a moiety selected from the group consisting of hydrogen, --COCH.sub.2 NH.sub.2, --COCH.sub.2 NHCONH.sub.2 and --COCH.sub.2 NHCHO; process for preparation thereof; and biologically pure culture for use therein.

Abstract: An antibiotic substance KA-7038 selected from the group consisting of the compounds having formulae I to VII described in claim 1, mixtures thereof and acid addition salts thereof; an antibiotic composition composed of (i) antibiotically effective amount of aforesaid antibiotic substance KA-7038, and (ii) a pharmaceutically acceptable diluent or carrier. The antibiotic substance KA-7038 can be produced by cultivating an antibiotic substance KA-7038-producing strain belonging to genus Streptomyces, for example Streptomyces sp. KC-7038, and isolating the antibiotic substance KA-7038 from the culture broth.

Abstract: Novel antibiotics of the following structure ##STR1## wherein R represents a moiety selected from the group consisting of hydrogen, --COCH.sub.2 NH.sub.2, --COCH.sub.2 NHCONH.sub.2 and --COCH.sub.2 NHCHO;process for preparation thereof; and biologically pure culture for use therein.